Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine in Relapsed/Refractory Neuroblastoma
NCT03794349Phase 2Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jul 2019
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of eflornithine in neuroblastoma (2 arms), sponsored by Children's Oncology Group. Primary endpoint: Objective Response Rate. Started Jul 2019; status: active, not recruiting.
02
Drugs
eflornithine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03794349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794349.